Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Tauriga Sciences Inc. Completes Initial Purchase Order with Blink Charging Co. for 4 Level II Electric Vehicle Pedestal Charging Units


Posted on: 29 Jun 18

NEW YORK, NY, June 29, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced the completion of initial purchase order for 4 Level II Electric Vehicle (“EV”) Pedestal Charging Units (“EV Charge Units” or “EV Units”) from NASDAQ listed Blink Charging Co. (“Blink”).  The Company has identified two locations to install these EV Units, which it believes have the potential to attract a substantial level of EV driver traffic. 

Recall that on April 27, 2018, Tauriga announced the execution of a Reseller Agreement with Blink to assist Blink in expanding its already significant national electric vehicle charging network.  This Reseller Agreement, which was entered into by Tauriga’s wholly owned subsidiary Tauriga Biz Dev. Corp., provides the Company’s shareholders with a potential revenue opportunity through the sales revenue model expressed in such agreement.  By purchasing units outright, the Company is able to substantially increase its potential revenue share (as pertaining to those specific units that have been purchased and are owned outright by Tauriga).  Once these 4 initial EV Units are installed, the Company will update its shareholders and may opt to purchase additional EV Units over the course of the coming weeks and months.

Please see below, the link to Tauriga’s April 27, 2018 press release disclosing its Reseller Agreement with Blink Charging Co.

Link:https://finance.yahoo.com/news/blink-charging-company-enters-reseller-130000375.html

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments. The Company is currently evaluating potential acquisition candidates, as previously disclosed, to create lasting shareholder value. Additionally, the Company is working diligently to identify potential opportunities to generate revenue and leverage its considerable resources and expertise to build a diversified and sustainable business model.  Please visit our corporate website at www.tauriga.com

FORWARD-LOOKING STATEMENTS:

This press release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events.  These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones.  Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated.  Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission.  Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. 


CONTACT: CONTACT INFORMATION Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY  10022 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell #: (917) 796 9926 www.tauriga.comGlobeNewswire
globenewswire.com

Last updated on: 29/06/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.